JPWO2020138491A1 - - Google Patents
Info
- Publication number
- JPWO2020138491A1 JPWO2020138491A1 JP2020562548A JP2020562548A JPWO2020138491A1 JP WO2020138491 A1 JPWO2020138491 A1 JP WO2020138491A1 JP 2020562548 A JP2020562548 A JP 2020562548A JP 2020562548 A JP2020562548 A JP 2020562548A JP WO2020138491 A1 JPWO2020138491 A1 JP WO2020138491A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018245688 | 2018-12-27 | ||
| JP2018245688 | 2018-12-27 | ||
| PCT/JP2019/051605 WO2020138491A1 (ja) | 2018-12-27 | 2019-12-27 | 神経発達障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2020138491A1 true JPWO2020138491A1 (https=) | 2020-07-02 |
| JPWO2020138491A5 JPWO2020138491A5 (https=) | 2023-01-11 |
| JP7483630B2 JP7483630B2 (ja) | 2024-05-15 |
Family
ID=71127068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020562548A Active JP7483630B2 (ja) | 2018-12-27 | 2019-12-27 | 神経発達障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20220110889A1 (https=) |
| EP (1) | EP3903775A4 (https=) |
| JP (1) | JP7483630B2 (https=) |
| WO (1) | WO2020138491A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE056378T2 (hu) | 2013-09-13 | 2022-02-28 | Univ Chiba Nat Univ Corp | R-Ketamin és sójának alkalmazása gyógyszerekként |
| US11980595B2 (en) | 2018-02-15 | 2024-05-14 | National University Corporation Chiba University | Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases |
| WO2019213551A1 (en) | 2018-05-04 | 2019-11-07 | Perception Neuroscience, Inc. | Methods of treating substance abuse |
| IL312041A (en) | 2021-10-12 | 2024-06-01 | Perception Neuroscience Inc | R-ketamine salts and methods of using them |
| EP4493155A1 (en) | 2022-03-14 | 2025-01-22 | Perception Neuroscience, Inc. | Pharmaceutical formulations of r-ketamine |
| JP2023152104A (ja) * | 2022-04-01 | 2023-10-16 | 株式会社エル・エスコーポレーション | 認知機能の評価方法、及び、認知機能の評価装置 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150196501A1 (en) * | 2014-01-14 | 2015-07-16 | Children's Hospital Medical Center | Compositions and methods for treating an autism spectrum disorder |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19619665C2 (de) | 1996-05-15 | 2001-03-08 | Goedecke Ag | Racemattrennung von Ketamin |
| US20120225949A1 (en) * | 2009-08-14 | 2012-09-06 | Demitri Papalos | Compositions and methods for treating bipolar disorder |
| US9737531B2 (en) * | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| HUE056378T2 (hu) * | 2013-09-13 | 2022-02-28 | Univ Chiba Nat Univ Corp | R-Ketamin és sójának alkalmazása gyógyszerekként |
| EP3085366A1 (en) * | 2015-04-22 | 2016-10-26 | Institut du Cerveau et de la Moelle Epiniere-ICM | Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior |
| EP3442940A1 (en) * | 2016-04-11 | 2019-02-20 | Clexio Biosciences Ltd. | Deuterated ketamine derivatives |
| AU2018215056A1 (en) * | 2017-01-31 | 2019-08-08 | Charles E. Inturrisi | D-methadone and its derivatives for use in the treatment of disorders of the nervous system |
| US20200405663A1 (en) * | 2017-09-27 | 2020-12-31 | National University Corporation Chiba University | R-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition functional disorder |
-
2019
- 2019-12-27 WO PCT/JP2019/051605 patent/WO2020138491A1/ja not_active Ceased
- 2019-12-27 US US17/417,557 patent/US20220110889A1/en active Pending
- 2019-12-27 EP EP19906114.4A patent/EP3903775A4/en active Pending
- 2019-12-27 JP JP2020562548A patent/JP7483630B2/ja active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150196501A1 (en) * | 2014-01-14 | 2015-07-16 | Children's Hospital Medical Center | Compositions and methods for treating an autism spectrum disorder |
Non-Patent Citations (3)
| Title |
|---|
| JHONSON K. M. ET AL.: "Phencyclidine: it ain’t excitin’, but it sure is toxic", 13TH INTERNATIONAL CONGRESS ON AMINO ACIDS, PEPTIDES AND PROTEINS, vol. 45, JPN6020007935, 14 August 2013 (2013-08-14), pages 588 - 589, ISSN: 0005140698 * |
| MOHAMMADI A. ET AL.: "Dysfunction in Brain-Derived Neurotrophic Factor Signaling Pathway and susceptibility to Schizophren", CURR. GENE THER., vol. 18, JPN6020007937, May 2018 (2018-05-01), pages 45 - 63, ISSN: 0005140696 * |
| YANG C. ET AL.: "R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects", TRANSL. PSYCHIATRY, vol. 5, JPN6020007934, 1 September 2015 (2015-09-01), pages 632 - 1, ISSN: 0005140697 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020138491A1 (ja) | 2020-07-02 |
| JP7483630B2 (ja) | 2024-05-15 |
| EP3903775A1 (en) | 2021-11-03 |
| EP3903775A4 (en) | 2022-10-12 |
| US20220110889A1 (en) | 2022-04-14 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AA64 | Notification of invalidation of claim of internal priority (with term) |
Free format text: JAPANESE INTERMEDIATE CODE: A241764 Effective date: 20210928 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211011 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221227 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221227 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230830 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231018 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231228 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240313 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240404 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240501 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7483630 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |